Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2017 1
2018 4
2019 6
2020 9
2021 5
2022 8
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy.
Gazeau N, Liang EC, Wu QV, Voutsinas JM, Barba P, Iacoboni G, Kwon M, Ortega JLR, López-Corral L, Hernani R, Ortiz-Maldonado V, Martínez-Cibrian N, Martinez AP, Maziarz RT, Williamson S, Nemecek ER, Shadman M, Cowan AJ, Green DJ, Kimble E, Hirayama AV, Maloney DG, Turtle CJ, Gauthier J. Gazeau N, et al. Among authors: wu qv. Transplant Cell Ther. 2023 Jul;29(7):430-437. doi: 10.1016/j.jtct.2023.04.001. Epub 2023 Apr 7. Transplant Cell Ther. 2023. PMID: 37031746
Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells.
Cordeiro A, Bezerra ED, Hirayama AV, Hill JA, Wu QV, Voutsinas J, Sorror ML, Turtle CJ, Maloney DG, Bar M. Cordeiro A, et al. Among authors: wu qv. Biol Blood Marrow Transplant. 2020 Jan;26(1):26-33. doi: 10.1016/j.bbmt.2019.08.003. Epub 2019 Aug 13. Biol Blood Marrow Transplant. 2020. PMID: 31419568 Free PMC article. Clinical Trial.
Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: A real-world study.
Iovino L, Wu QV, Voutsinas J, Panaite L, Mullane E, Lynch RC, Ujjani C, Smith SD, Gopal AK, Till BG, Milano F, Chow V, Gauthier J, Turtle CJ, Maloney DG, Shadman M. Iovino L, et al. Among authors: wu qv. J Cell Mol Med. 2022 Dec;26(24):5976-5983. doi: 10.1111/jcmm.17550. Epub 2022 Dec 1. J Cell Mol Med. 2022. PMID: 36453136 Free PMC article.
Modified Manufacturing Process Modulates CD19CAR T-cell Engraftment Fitness and Leukemia-Free Survival in Pediatric and Young Adult Subjects.
Ceppi F, Wilson AL, Annesley C, Kimmerly GR, Summers C, Brand A, Seidel K, Wu QV, Beebe A, Brown C, Mgebroff S, Lindgren C, Rawlings-Rhea SD, Huang W, Pulsipher MA, Wayne AS, Park JR, Jensen MC, Gardner RA. Ceppi F, et al. Among authors: wu qv. Cancer Immunol Res. 2022 Jul 1;10(7):856-870. doi: 10.1158/2326-6066.CIR-21-0501. Cancer Immunol Res. 2022. PMID: 35580141 Free PMC article. Clinical Trial.
Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitors.
Pan C, Wu QV, Voutsinas J, Houlton JJ, Barber B, Rizvi ZH, Marchiano E, Futran N, Laramore GE, Liao JJ, Parvathaneni U, Martins RG, Fromm JR, Rodriguez CP. Pan C, et al. Among authors: wu qv. Cancer Med. 2023 Apr;12(8):9384-9391. doi: 10.1002/cam4.5697. Epub 2023 Feb 21. Cancer Med. 2023. PMID: 36806947 Free PMC article.
Neutrophil to lymphocyte ratio and peripheral blood biomarkers correlate with survival outcomes but not response among head and neck and salivary cancer treated with pembrolizumab and vorinostat.
Pan C, Wu QV, Voutsinas J, Houlton JJ, Barber B, Futran N, Laramore GE, Liao JJ, Parvathaneni U, Martins RG, Fromm JR, Rodriguez CP. Pan C, et al. Among authors: wu qv. Head Neck. 2023 Feb;45(2):391-397. doi: 10.1002/hed.27252. Epub 2022 Nov 22. Head Neck. 2023. PMID: 36412064 Free PMC article. Clinical Trial.
Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up.
Ho C, Gopal AK, Till BG, Shadman M, Lynch RC, Cowan AJ, Wu QV, Voutsinas J, Rasmussen HA, Blue K, Ujjani CS, Cassaday RD, Fromm JR, Fang M, Smith SD. Ho C, et al. Among authors: wu qv. Clin Lymphoma Myeloma Leuk. 2024 Feb;24(2):e33-e39.e1. doi: 10.1016/j.clml.2023.10.002. Epub 2023 Oct 18. Clin Lymphoma Myeloma Leuk. 2024. PMID: 37926672
30 results